# A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)

> **NCT05616754** · PHASE3 · UNKNOWN · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
- **BIOLOGICAL:** Recombinant Novel Coronavirus Protein Vaccine (CHO cells)

## Key facts

- **NCT ID:** NCT05616754
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-07
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05616754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05616754, "A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05616754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*